US20050143559A1 - Tryparedoxin, expression plasmid, process of preparation, method of use, test kit and pharmaceutical composition - Google Patents

Tryparedoxin, expression plasmid, process of preparation, method of use, test kit and pharmaceutical composition Download PDF

Info

Publication number
US20050143559A1
US20050143559A1 US10/962,760 US96276004A US2005143559A1 US 20050143559 A1 US20050143559 A1 US 20050143559A1 US 96276004 A US96276004 A US 96276004A US 2005143559 A1 US2005143559 A1 US 2005143559A1
Authority
US
United States
Prior art keywords
tryparedoxin
protein
polypeptide
txn
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/962,760
Inventor
Leopold Flohe
Everson Nogoceke
Henryk Kalisz
Marisa Montemartini
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US10/962,760 priority Critical patent/US20050143559A1/en
Publication of US20050143559A1 publication Critical patent/US20050143559A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • Flagellated protozoan parasites of the family Trypanosomatidae are among the most prevalent human pathogens in tropical and subtropical areas. These organisms have complex life cycles and some of them are the causative agents of debilitating or life-threatening diseases, such as American Chagas' disease ( Trypanosoma cruzi ), African sleeping sickness ( T. brucei ganibienise and T. b. rhodesienise ), oriental sore ( Leishmania tropica ), kala azar ( L. donovani ) and mucocutaneous leishmaniasis ( L. brasiliensis ).
  • American Chagas' disease Trypanosoma cruzi
  • African sleeping sickness T. brucei ganibienise and T. b. rhodesienise
  • oriental sore Leishmania tropica
  • kala azar L. donovani
  • mucocutaneous leishmaniasis L. brasiliensis
  • Nifurtimox for instance, a drug widely used in the treatment of Chagas' disease, is an unspecific redox cycler affecting not only the peroxide sensitive parasites but also the host. Accordingly, the defense system against oxidants in the trypanosomatids, which differs substantially from the analogous host metabolism, has been discussed as a potential target area for the development of more specific trypanocidal agents. (Fairlamb, 1996; Jacoby et al., 1996).
  • the trypanosomatids are inevitably exposed to various reactive oxygen species, such as superoxide radicals, hydrogen peroxide and myeloperoxidase products, generated during the host defense reaction.
  • reactive oxygen species such as superoxide radicals, hydrogen peroxide and myeloperoxidase products
  • their ability to cope with such oxidative stress appears to be surprisingly weak.
  • they possess an iron-containing superoxide dismutase to scavenge phagocyte-derived superoxide (LeTrant et al., 1983)
  • most of them lack both catalase and glutathione peroxidase (Docampo, 1990), the major hydroperoxide metabolising enzymes of the host organisms (Chance et al., 1979; Flohe, 1989).
  • GSH glutathione
  • T(SH) 2 trypanothione
  • N 1 ,N 8 -bis(glutathionyl)spermidine trypanothione
  • FIG. 1 trypanothione
  • T(SH) 2 can be oxidized by H 2 O 2 to the corresponding cyclic disulphide (TS 2 ) ( FIG.
  • T(SH) 2 is regenerated at the expense of NADPH by trypanothione reductase (TR; Bailey et al., 1993; Jacoby et al., 1996) ( FIG. 1 ).
  • TR trypanothione reductase
  • FIG. 1 Whether the reaction of T(SH) 2 with H 2 O 2 is enzymatically catalyzed has, however, been the subject of debate.
  • a T(SH) 2 -dependent peroxidase activity was repeatedly reported for crude extracts of the trypanosomatids (Penketh and Klein, 1986; Henderson et al., 1987; Penketh et al., 1987).
  • the present invention is based on the discovery that hydroperoxide metabolism in the trypanosomatids is enzymatic in nature, but distinct from any known metabolic pathway of the host organisms (Nogoceke et al., 1997). Apart from the previously known trypanothione reductase (TR), the parasitic pathway comprises two novel proteins, called tryparedoxin (TXN) and tryparedoxin peroxidase (TXNPx), which together catalyse the reduction of hydroperoxides at the expense of NADPH as depicted in FIG. 1 . Isoforms of tryparedoxin exist in one species.
  • one embodiment of the invention concerns proteins, which we called tryparedoxins (trypanothione: peroxiredoxin oxidoreductases) and which are characterized by their capability of transferring reductive equivalents of trypanothione to a peroxiredoxin-type protein such as tryparedoxin peroxidase.
  • tryparedoxins trypanothione: peroxiredoxin oxidoreductases
  • peroxiredoxin-type proteins such as tryparedoxin peroxidase.
  • Tryparedoxins exhibit a catalytic site similar to that of thioredoxin, an ubiquituous redox mediator with pleiotropic functions. Typical thioredoxins have never been found in any trypanosomatid. It therefore appears conceivable that in the trypanosomatids the tryparedoxins substitute for thioredoxin in such diverse metabolic functions as reduction of ribonucleotides, differentiation, regulation of transcription or other regulatory processes depending on the cellular thiol/disulphide equilibrium. The possibility of multiple biological functions of tryparedoxins is further suggested by the coexistence of more than one tryparedoxin in the same species, as described below.
  • the proteins according to the invention can be characterized in that they can be prepared by means of and/or isolated from a species of the family Trypanosomatidae.
  • proteins according to the invention can be characterized in that their preparation and/or isolation can be carried out by genetic engineering, especially by means of an oligonucleotide as probe having the oligonucleotide sequence and encoding the amino acid sequence of SEQ ID NO 1 ( FIG. 2 ) or any useful part thereof.
  • proteins according to the invention can be characterized by a molecular weight of 15-19 kDa.
  • a protein according to the invention can be characterized by a WCPPC motif and catalyzing the reduction of protein disulphide bonds by means of trypanothione.
  • a protein according to the invention can be a protein
  • the protein according to (b) can be a protein having an amino acid sequence which is homologous to SEQ ID NO 1 or SEQ ID NO 2 by at least 70% and especially at least 75%.
  • Another embodiment of the invention concerns plasmids for the expression of proteins according any of the preceding claims and comprising a nucleic acid sequence encoding said proteins.
  • the plasmids according to the invention may comprise DNA sequences encoding tryparedoxin especially of Crithidia fasciculata.
  • a plasmid according to the invention may comprise a DNA sequence encoding functionally active derivatives of tryparedoxin designed for the isolation in a manner known per se.
  • a plasmid according to the invention may comprise a DNA sequence encoding functionally active derivatives of tryparedoxin wherein the tryparedoxin is derivatised by a His tag.
  • Still another embodiment of the invention concerns a process for the production of a protein according to the invention characterized in that it is produced by means of a DNA sequence encoding the amino acid sequence of SEQ ID NO 2 by genetic engineering in a manner known per se.
  • the process according to the invention can be characterized in that the production is carried out by means of a plasmid according to the invention.
  • the process according to the invention can be characterized in that the host is selected from the group consisting of bacteria, fungi, yeast, plant cells, insect cells, mammalian cells and cell cultures (heterologous expression).
  • the process according to the invention can be characterized in that Escherichia coli is used as host.
  • Still another embodiment of the invention concerns the use of a protein according to the invention for testing and recovering inhibitory substances which inhibit activities of said protein.
  • Still another embodiment of the invention concerns a test system for testing the catalytic activity of a protein according to the invention or obtained according to the process according to the invention, wherein the testing system contains or comprises trypanothione, trypanothione reductase, a tryparedoxin peroxidase, a tryparedoxin and, in addition, a hydroperoxide as indicator enzyme, mediator and substrate, respectively.
  • another embodiment of the invention concerns a pharmaceutical preparation having a trypanocidal activity and comprising an inhibitory substance inhibiting the catalytic activity of a protein according to the invention or of a protein which can be obtained according to the process according to the invention.
  • the pharmaceutical composition according to the invention can be characterized in that it can be obtained by a use according to the invention and by using a test system according to the invention.
  • FIG. 1 Flux of reducing equivalents from NADPH to hydroperoxide in C. fasciculata.
  • TR trypanothione reductase
  • T(SH) 2 trypanothione
  • TS 2 trypanothione disulphide
  • TXN tryparedoxin
  • TXNPx tryparedoxin peroxidase
  • ROOH hydroperoxide.
  • FIG. 2 Nucleotide sequence and deduced amino acid sequences of the PCR product used to screen a genomic library for inserts containing the tryparedoxin I gene. Partial sequences confirmed by protein sequence analysis are underlined and the sequences corresponding to the primers used to obtain the PCR product are double underlined.
  • FIG. 3 Nucleotide and amino acid sequences of tryparedoxin II isolated from a C. fasciculata genomic library. The start and stop codons are in bold. The position of the Pvu II site from which one third of the gene at the 5′ end of the open reading frame was determined is double underlined. The WCPPC thioredoxin-like motif is underlined.
  • FIG. 4 Components of the trypanothione-mediated hydroperoxide metabolising system from C. fasciculata in silver-stained SDS-PAGE (8-25%). Lane 2, extract of disrupted cells; lane 3, trypanothione reductase, lane 4, tryparedoxin peroxidase and lane 5, tryparedoxin I. Lanes 1 and 6, molecular weight standards.
  • FIG. 5 Molecular mass determination by MALDI-TOF of pure tryparedoxin I from C. fasciculata (trace A), tryparedoxin I exposed to iodoacetamide (trace B), T(SH)2-reduced tryparedoxin I derivatized with iodoacetamide (trace C) and with iodoacetamide plus N-ethylmaleimide (trace D).
  • the mass increments shown in traces C and D correspond to the addition of one carboxyamidomethyl residue (observed 54 Da, theoretical 57 Da) and one carboxyamidomethyl plus one N-ethylsuccinimide residue (observed 185 Da, theoretical 182 Da), respectively.
  • FIG. 6 NADPH-dependent hydroperoxide metabolism reconstituted from components isolated from C. fasciculata. Peroxidase activity depends on both isolated proteins, tryparedoxin I (TXN I) (A) and tryparedoxin peroxidase (TXNPx) (B), as well as T(SH) 2 (E) and trypanothione reductase (TR) (F). The comparatively high activity in (F) observed immediately after the addition of TR is due to the accumulation of its substrate, TS 2 . Note that the reaction is comparably fast with H 2 O 2 (D) and t-bOOH (C). The tests were performed at 27° C.
  • NADPH consumption was measured photometrically at 340 nm.
  • FIG. 7 Sequence alignment of the peptide fragments of tryparedoxin I with thioredoxin-like protein of Caenorhabditis elegans (TLP/CE).Tryparedoxin I was digested with trypsin (Tryp) or endoproteinase Glu-C (Glu-C). Asterisks denote conserved residues.
  • FIG. 8 Tryparedoxin II containing a His tag specific activity determined in the supernatants of sonicated E. coli BL21(DE3)pET24a cells (black square) and E. coli BL2 I (DE3)pET/TXN II H6 cells (black circle).
  • Gene expression induction by isopropyl- ⁇ -D-thiogalactopyranoside addition is indicated by an arrow.
  • FIG. 9 Western blot analysis of expressed tryparedoxin II containing a His tag SDS-PAGE was done under reducing conditions in 8-25% gradient gels on a Pharmacia Pliast System and the samples were electroblotted onto a PVDF membrane using a Pharmacia Phast System.
  • Lane 1 supernatant of E. coli BL21(DE3) pET/TXN II H6 cells 6 h after induction; lane 2, purified recombinant tryparedoxin II; lane 3, authentic tryparedoxin I from C. fasciculata.
  • FIG. 10 Tryparedoxin II specific activity determined in the supernatants of sonicated E. coli BL21(DE3)pET24a cells (black square) and E. coli BL-21(DE3)pET/TXN II cells (black rhomb).
  • Gene expression induction by isopropyl- ⁇ -D-thiogalactopyranoside addition is indicated by an arrow.
  • FIG. 11 Western blot analysis of expressed tryparedoxin II.
  • SDS-PAGE was done under reducing conditions in 8-25% gradient gels on a Pharmacia Phast System and the samples were electroblotted onto a PVDF membrane using a Pharmacia Phast System.
  • Whole rabbit serum (1:500 dilution) containing antibodies raised against pure C. fasciculata tryparedoxin I was used as primary antibody and anti-rabbit goat antibodies (Sigma) as secondary antibody.
  • Lane 1 authentic tryparedoxin I from C. fasciculata
  • lane 2 supernatant of E. coli BL21(DE3) pET/TXN II cells 6 h after induction.
  • FIG. 12 SDS-PAGE of expressed tryparedoxin II containing a His tag. SDS-PAGE was done under reducing conditions in 8-25% gradient gels on a Pharmacia Phast System and the gels were stained for protein with silver according to the manufacturers' recommendations. Lane 2, supernatant of E. coli BL21(DE3) pET24a cells after 6h induction; lane 2, supernatant of E. coli BL21(DE3) pET/TXN II H6 cells 6 h after induction; lane 3, purified recombinant tryparedoxin II; lane 4, authentic tryparedoxin I from C. fasciculata. Lanes 1 and 6, molecular weight standards.
  • C. fasciculata was cultivated in a 100 I fermenter as described (Shim and Fairlamb, 1988). The cells were harvested in the late log phase, suspended in 50 mM sodium phosphate pH 5.8 (buffer B) containing 0.1 mM PMSF, then frozen and thawed twice to complete cell disruption. Cell debris was removed by centrifugation at 25,000 ⁇ g for 30 min and the supernatant was applied on an S-Sepharose column pre-equilibrated with buffer B. Tryparedoxin peroxidase eluted at 150 mM NaCl in buffer B and was directly loaded on a hydroxyapatite (BioRad, USA) column pre-equilibrated with 10 mM sodium phosphate pH 6.8.
  • Tryparedoxin peroxidase was eluted stepwise with 0.4 M potassium phosphate pH 6.8.
  • the protein was extensively dialyzed against 20 mM Tris pH 7.6 (buffer C) and purified to homogeneity on a Resource Q column, eluting at 0.1 M NaCl in buffer C.
  • the flow-through of the S-Sepharose column containing trypanothione reductase and tryparedoxin can be used to measure the enzymatic activity of tryparedoxin peroxidase (see example 2).
  • the flow-through of the S-Sepharose column, containing trypanothione reductase and tryparedoxin was adjusted to pH 7.2 with 1 M NaOH.
  • the extract was adjusted to 3% (w/v) streptomycin sulphate, brought to 50%. ammonium sulphate saturation, and centrifuged for 10 min at 11,000 ⁇ g. The supernatant was adjusted to 80% ammonium sulphate saturation and recentrifuged. The pellet was dissolved in, then dialyzed extensively, against 20 mM bis-Tris propane pH 7.2 containing 1 mM EDTA and 1 mM DTT (buffer D). The enzyme extract was loaded on a DEAE-Sepharose column and eluted with a linear gradient of 0.4 M KCl in buffer D.
  • the sample eluting at 80-120 mM KCl was concentrated by ultrafiltration (Omegacell, Filtron, Germany), washed with 20 mM potassium phosphate pH 7.2 containing 1 mM EDTA and 1 mM DTT (buffer E) and loaded on a 2′5′ADP-Sepharose 4B column. Trypanothione reductase was eluted with 5 mM NADP in buffer E and purified to homogeneity on a Sephacryl S-200 column.
  • tryparedoxin I The authentic tryparedoxin, thus isolated, is termed tryparedoxin I (TXN I).
  • TXN I The overall yields of the final purification scheme are shown in Table 1. TABLE 1 Yields and purification factors during the isolation of tryparedoxin I.
  • an assay sample may contain 0.1 mM NADPH in 50 mM Hepes pH 7.6, 1 mM EDTA, 50 M H 2 O 2 or t-butyl hydroperoxide (t-bOOH), 45 M T(SH) 2 , 16.5 ⁇ g/ml tryparedoxin peroxidase and 0.34 U trypanothione reductase and an unknown amount of tryparedoxin.
  • t-BOOH may be replaced by other hydroperoxides, such as H 2 O 2 , linoleic acid hydroperoxide or phosphatidylcholine hydroperoxide.
  • FIG. 6 demonstrates that trypanothione reductase, T(SH) 2 , tryparedoxin and tryparedoxin peroxidase are indispensable for the efficient reduction of H 2 O 2 or alkyl hydroperoxides by NADPH.
  • T(SH) 2 -mediated “NADPH peroxidase activity” of C. fasciculata is thus achieved by the concerted action of three distinct proteins; the well characterized trypanothione reductase (Bailey et al., 1993), tryparedoxin and tryparedoxin peroxidase.
  • tryparedoxin I Since the N-terminus of tryparedoxin I was blocked, the protein was digested with either bovine trypsin or endoproteinase Glu-C from Staphylococcus aureus (both sequencing grade, Promega) according to Stone and Williams (1993).
  • the peptides were separated by HPLC (Applied Biosystems 172A) on an Aquapore OD-300 RP-18 column. Automated Edman degradation was performed with an Applied Biosystems, Inc. sequencer with an on-line C-18 reverse phase HPLC. Database searches were performed with the BLAST and FASTA programs. Peptides were aligned with the Bestfit program, Genetics Computer Group (GCG), Madison, Wis., USA.
  • Seven fragments could be sequenced and could be aligned to a thioredoxin-like protein of C. elegans ( FIG. 7 ).
  • C. fasciculata (HS6) was grown as described by Shim and Fairlamb (1988). The cells were harvested by centrifugation for 15 min at 7000 rpm, washed twice with saline solution (0.9% NaCl) and resuspended in 5 ml buffer (50 mM TrisHCl, 100 mM EDTA, 15 mM NaCl, 0.5% SDS, 100 ⁇ g ml ⁇ 1 Proteinase K, pH 8.0). Resuspended cells were preincubated at 50° C. for 40 min. The genomic DNA was extracted twice with equivalent volumes of phenol (incubation: 60° C.
  • Genomic DNA was precipitated with sodium acetate and ethanol.
  • the PCR product was analysed by agarose gels and purified using the QIAquick PCR purification kit (QIAGEN Inc.). Sequencing was performed on a 373A DNA Sequencer (Applied Biosystems) using the PRISM Ready Reaction DyeDeoxy Terminator Sequencing Kit (1550V, 19 mA, 30 W, 42° C.). When used as a hybridization probe the PCR product was labelled with digoxigenin using the DIG DNA Labeling Kit (Boehringer Mannheim) according to the instructions provided by the supplier.
  • the genomic DNA was partially digested for 5-30 min with a ratio unit Sau3A / ⁇ g DNA of 0.005. The efficiency of the digestion was monitored by electrophoresis on agarose gels. Proteins were removed from the DNA using StrataClean Resin (Stratagene). The Sau3A sites were partially refilled with dATP and dGTP and Klenow fragment. The genomic DNA was ligated into Lambda GEM-11 Xho I half site arms (Promega) at a molar ratio of DNA to genomic DNA (average size 15 kb) of 1:0.7. The ligated DNA was packaged using the Packagene Lambda DNA Packaging System (Promega) according to the suppliers' instructions.
  • the phages were used to infect the E. coli host strain LE392 (Promega) according to the standard protocol. 5.1 ⁇ 10 3 pfu of the genomic library were plated on agar. The plaques were transferred to 9 cm diameter Biodyne-A nylon membranes and screened with the DIG-labelled PCR probes following the instructions provided by the supplier but using a hybridization temperature of 54 C. DIG labelled nucleic acids were detected calorimetrically with the DIG Nucleic Acid Detection Kit (Boehringer Mannheim). Positive clones were rescreened, amplified and suspended in SM buffer. The phages were precipitated by PEG 8000 and purified in CsCl gradients.
  • the isolated DNA was used for restriction analyses (Sac I, EcoR I, BamH I, Xho I, Nco I) or as template for PCR reactions.
  • the digestion products were eluted from agarose gels and ligated into pBluescript II KS ( ⁇ ) phagemids (Stratagene) or pET24d(+) vector (Novagen).
  • the ligated DNA was used to transform E. coli LE392.
  • Transformed cells were selected by ampicillin (pBluescript II KS ( ⁇ ) phagemid) or kanamycin (pET24d(+) vector) resistance, plasmids were purified using QIAprep Spin Plasmid Kit (Qiagen Inc.) and analyzed by restriction enzyme digestion and sequencing.
  • a clone containing a 22 kb insert with the presumed tryparedoxin I gene was isolated.
  • the DNA was digested with the restriction enzyme Sac I to separate the phage arms from the insert and with the restriction enzyme Nco I.
  • a southern blot was performed and a fragment of 6 kb hybridized with the labelled PCR product.
  • the fragment was subcloned into the pET24d(+) vector (Novagen). Subsequent digestion of the cloned fragment with the restriction enzyme Pvu II led to the isolation and cloning of a 1 kb fragment.
  • this fragment was sequenced it contained only one third of the gene coding for tryparedoxin at the 5′ end of the open reading frame ( FIG. 3 ).
  • the DNA sequence thus obtained was in full agreement with the peptide sequence derived from the isolated tryparedoxin I.
  • New primers were designed using the information obtained in example 4 and the complete gene was sequenced directly from the 6 kb fragment.
  • the previously obtained PCR product is about 60% identical in its amino acid sequence to the correponding region of the isolated gene.
  • the full length encoding DNA and the deduced amino acid sequence are shown in FIG. 3 .
  • the gene encodes for a protein with a molecular mass of 17000, while the molecular mass of natural tryparedoxin I isolated from C. fasciculata is 16393 ⁇ 10 (Nogoceke et al.,1997).
  • the tryparedoxin gene contained in the cloned 6 kb fragment was amplified by PCR with a forward primer A (5′-TCGTGATTCCGTTCCGCATATGTCAGGGC-3′) that contains an Nde I site and overlaps the 5′ end of the coding sequence, and a reverse primer B. (5′-GCAACTCAATCGCTCCCCTCGAGCTTCTTGGCCTCC-3′) which overlaps the 3′ end of the coding sequence and contains an Xho I site. Consequently a leucine and a glutamate residue are added, the stop codon is deleted and the protein will contain 6 histidine residues at its carboxyl-terminal end.
  • Amplification was performed as above but using the Expand High Fidelity polymerase mixture and buffer (Boehringer Mannheim) at an annealing temperature of 50° C. with the extension temperature being increased in 10 sec increments per cycle during cycles 10-20.
  • the amplified coding region was digested with Nde I and Xho I and ligated to a pET24a(+) vector (Novagen) treated with the same enzymes and dephosphorylated.
  • the resulting plasmid (pET/TXN II H6) was used to transform E. coli BL21(DE3). Transformed cells were selected by kanamycin resistance, the plasmids purified and sequenced.
  • reverse primer C 5′- CAGCAACTCAATGGATCC TCATTACTTCTTGGCC-3′
  • reverse primer B 5′- CAGCAACTCAATGGATCC TCATTACTTCTTGGCC-3′
  • the reverse primer contained an extra stop codon and a BamH I site at the 5′-end of the extra stop codon, with the digestions for the cloning step being performed with Nde I and BamH I.
  • the resulting plasmid was called pET/17 II and was used to transform E. coli BL21(DE3). Transformed cells were selected by kanamycin resistance, the plasmids purified and sequenced.
  • E. coli BL21(DE3) pET/TXN IIH6 were grown to A 600 of 0.9-1.0 at 25° C. and 180 rpm in LB medium with 30 ⁇ g kanamycin/ml, then expression of the tryparedoxin II gene was induced with 1 mM isopropyl-D-thiogalactopyranoside.
  • E. coli BL21(DE3) containing the pET24a plasmid was grown in the same way. Samples taken at, different times were centrifuged, resuspended in 50 mM Tris-HCl pH 8.0, 1 mM EDTA buffer, sonicated and centrifuged. Enzyme activity was determined as in Nogoceke et al.
  • E. coli BL21(DE3) pET/TXN II were grown to A 600 of 0.9-1.0 at 25° C. and 180 rpm in LB medium with 30 ⁇ g kanamycin/ml, then expression of the tryparedoxin II gene was induced with 1 mM isopropyl-D-thiogalactopyranoside.
  • E. coli BL21(DE3) containing the pET24a plasmid was grown in the same way. Samples taken at different times were centrifuged, resuspended in 50 mM Tris-HCl pH 8.0, 1 mM EDTA buffer, sonicated and centrifuged. Enzyme activity was determined as in Nogoceke et al.
  • E. coli BL21(DE3) pET/TXN II H6 was grown at 25° C. and 180 rpm in LB medium with 30 ⁇ g kanamycin/ml to A 600 of 0.9-1.0, then expression of the tryparedoxin II gene was induced with 1 mM isopropyl-D-thiogalactopyranoside. After 6 h the culture was centrifuged and either stored at ⁇ 20° C. or the cells were resuspended in 0.05 culture volumes of binding buffer (5 mM imidazole, 500 mM NaCl and 20 mM Tris-HCl pH 7.9).
  • binding buffer 5 mM imidazole, 500 mM NaCl and 20 mM Tris-HCl pH 7.9
  • the cell suspension was sonicated on ice and centrifuged for 40 min at 4° C., 13000 rpm. The supernatant was applied to a His Bind resin (Novagen) column charged with Ni 2+ and equilibrated with binding buffer, at a flow rate of about 10 column volumes per hour. The column was washed with 10 volumes of binding buffer and 6 volumes of 500 mM NaCl, 20 mM Tris-HCl pH 7.9 buffer containing 100 mM imidazole. Tryparedoxin eluted in the buffer containing 500 mM imidazole.
  • the difference in the molecular mass between the recombinant and authentic tryparedoxin peroxidase corresponded mainly to the additional amino acids (leucine, glutamate and 6 histidine residues) added at the C-terminal end of the recombinant enzyme.
  • the purified recombinant enzyme had a specific activity of 7.7 U/mg compared to 2.3 U/mg for the authentic enzyme.
  • the test system described in example 2 is easily adapted to screen compounds for specific inhibition of tryparedoxin I.
  • S-modifying agents such as N-ethylmaleimide (NEM), iodoacetamide (IAM) and phenylarsine oxide (PAO) is described (Table 2).
  • NEM N-ethylmaleimide
  • IAM iodoacetamide
  • PAO phenylarsine oxide
  • Tryparedoxin was preincubated in 50 mM Hepes, 1 mM EDTA, pH 7.6 with or without presumed reducing substrate (T(SH) 2 ), then reacted with inhibitors and activity was checked at 22° C. essentially as described in example 2. Changes in molecular mass were determined by MALDI-TOF-MS ( FIG. 5 ).
  • Tryparedoxin was preincubated in 50 mM Hepes, 1 mM EDTA, pH 7.6 with presumed reducing substrates, then reacted with iodoacetamide (IAM), NEM or phenylarsine oxide (PAO). Changes in molecular mass were determined my MALDI-TOF-MS. Residual activity was measured at 22° C. using 1 mM T(SH) 2 with 1.0 ⁇ M tryparedoxin peroxidase and 0.6 ⁇ M tryparedoxin.
  • IAM iodoacetamide
  • PAO phenylarsine oxide

Abstract

The present invention provides novel enzymes, tryparedoxins, their isolation from Crithidia fasciculata, a method for the production thereof in genetically transformed bacteria, and their use as molecular targets for the discovery of trypanocidal drugs

Description

  • This is a continuation of International Application No. PCT/EP97/06983 filed Dec. 12, 1997, the entire disclosure of which is incorporated herein by reference.
    • INTRODUCTION
  • Flagellated protozoan parasites of the family Trypanosomatidae are among the most prevalent human pathogens in tropical and subtropical areas. These organisms have complex life cycles and some of them are the causative agents of debilitating or life-threatening diseases, such as American Chagas' disease (Trypanosoma cruzi), African sleeping sickness (T. brucei ganibienise and T. b. rhodesienise), oriental sore (Leishmania tropica), kala azar (L. donovani) and mucocutaneous leishmaniasis (L. brasiliensis). Others infect hosts as diverse as plants (Phytomonas species), insects (Crithidia and Leptomonas species) and livestock (T. congolenise, T. b. brucei, T. evansi). Many of the human pathogens are also endemic in wildlife. Worldwide, more than 30 million people are estimated to suffer from trypanosomal and leishmanial infections (World Health Organisation, 1996). Vaccination strategies have so far failed and most of the chemotherapeutic drugs currently used for treatment are unsatisfactory in terms of both efficacy and toxicity (Risse, 1993). Nifurtimox, for instance, a drug widely used in the treatment of Chagas' disease, is an unspecific redox cycler affecting not only the peroxide sensitive parasites but also the host. Accordingly, the defense system against oxidants in the trypanosomatids, which differs substantially from the analogous host metabolism, has been discussed as a potential target area for the development of more specific trypanocidal agents. (Fairlamb, 1996; Jacoby et al., 1996).
  • As parasites, the trypanosomatids are inevitably exposed to various reactive oxygen species, such as superoxide radicals, hydrogen peroxide and myeloperoxidase products, generated during the host defense reaction. However, their ability to cope with such oxidative stress appears to be surprisingly weak. Although they possess an iron-containing superoxide dismutase to scavenge phagocyte-derived superoxide (LeTrant et al., 1983), most of them lack both catalase and glutathione peroxidase (Docampo, 1990), the major hydroperoxide metabolising enzymes of the host organisms (Chance et al., 1979; Flohe, 1989). They also contain conspicuously low concentrations of glutathione (GSH), the major antioxidant sulfhydryl compound in mammalian cells. Instead they form a unique GSH derivative known as trypanothione (T(SH)2; N1,N8-bis(glutathionyl)spermidine) (FIG. 1), which is believed to play a central role in their antioxidant defense system (Fairlamb et al., 1985; Fairlamb and Cerami, 1992). T(SH)2 can be oxidized by H2O2 to the corresponding cyclic disulphide (TS2) (FIG. 1) and is regenerated at the expense of NADPH by trypanothione reductase (TR; Bailey et al., 1993; Jacoby et al., 1996) (FIG. 1). Whether the reaction of T(SH)2 with H2O2 is enzymatically catalyzed has, however, been the subject of debate. A T(SH)2-dependent peroxidase activity was repeatedly reported for crude extracts of the trypanosomatids (Penketh and Klein, 1986; Henderson et al., 1987; Penketh et al., 1987). However, a pertinent enzymatic entity could never be purified (Henderson et al., 1987; Penketh et al., 1987) and doubts about its existence were raised (Penketh and Klein, 1986). A recent systematic investigation of the various developmental stages of T. cruzi even concluded that non-enzymatic oxidation of T(SH)2 by H2O2 may fully account for the slow hydroperoxide metabolism in this species (Carnieri et al., 1993).
  • The present invention is based on the discovery that hydroperoxide metabolism in the trypanosomatids is enzymatic in nature, but distinct from any known metabolic pathway of the host organisms (Nogoceke et al., 1997). Apart from the previously known trypanothione reductase (TR), the parasitic pathway comprises two novel proteins, called tryparedoxin (TXN) and tryparedoxin peroxidase (TXNPx), which together catalyse the reduction of hydroperoxides at the expense of NADPH as depicted in FIG. 1. Isoforms of tryparedoxin exist in one species.
  • The uniqueness of this cascade of oxidoreductases offers the possibility to inhibit the parasitic metabolism without causing adverse effects in the host organism.
  • Thus, one embodiment of the invention concerns proteins, which we called tryparedoxins (trypanothione: peroxiredoxin oxidoreductases) and which are characterized by their capability of transferring reductive equivalents of trypanothione to a peroxiredoxin-type protein such as tryparedoxin peroxidase. As regards peroxi-redoxins and peroxi-redoxin-type proteins, reference is made to Chae et al. in J. Biol. Chem., 269(1994) 27670-24678 and in PNAS USA, 91 (1994) 7017-7021 and to EP 96 120 016.9 or PCT/EP 97/04 990. Tryparedoxins exhibit a catalytic site similar to that of thioredoxin, an ubiquituous redox mediator with pleiotropic functions. Typical thioredoxins have never been found in any trypanosomatid. It therefore appears conceivable that in the trypanosomatids the tryparedoxins substitute for thioredoxin in such diverse metabolic functions as reduction of ribonucleotides, differentiation, regulation of transcription or other regulatory processes depending on the cellular thiol/disulphide equilibrium. The possibility of multiple biological functions of tryparedoxins is further suggested by the coexistence of more than one tryparedoxin in the same species, as described below.
  • The proteins according to the invention can be characterized in that they can be prepared by means of and/or isolated from a species of the family Trypanosomatidae.
  • Further, the proteins according to the invention can be characterized in that their preparation and/or isolation can be carried out by genetic engineering, especially by means of an oligonucleotide as probe having the oligonucleotide sequence and encoding the amino acid sequence of SEQ ID NO 1 (FIG. 2) or any useful part thereof.
  • Further, the proteins according to the invention can be characterized by a molecular weight of 15-19 kDa.
  • Further, a protein according to the invention can be characterized by a WCPPC motif and catalyzing the reduction of protein disulphide bonds by means of trypanothione.
  • Further, a protein according to the invention can be a protein
      • (a) having the amino acid sequence SEQ ID NO 2 (FIG. 3, positions 1 to 150) or
      • (b) having an amino acid sequence which is homologous to said according to (a), has the same number or a smaller or slightly smaller or larger number of amino acids than SEQ ID NO 2 and is encoded by an oligonucleotide which is hybridizable with an oligonucleotide which encodes a protein comprising or having the amino acid sequence SEQ ID NO 1 or SEQ ID NO 2.
  • Further, the protein according to (b) can be a protein having an amino acid sequence which is homologous to SEQ ID NO 1 or SEQ ID NO 2 by at least 70% and especially at least 75%.
  • Another embodiment of the invention concerns plasmids for the expression of proteins according any of the preceding claims and comprising a nucleic acid sequence encoding said proteins.
  • The plasmids according to the invention may comprise DNA sequences encoding tryparedoxin especially of Crithidia fasciculata.
  • Further, a plasmid according to the invention may comprise a DNA sequence encoding functionally active derivatives of tryparedoxin designed for the isolation in a manner known per se.
  • Further, a plasmid according to the invention may comprise a DNA sequence encoding functionally active derivatives of tryparedoxin wherein the tryparedoxin is derivatised by a His tag.
  • Still another embodiment of the invention concerns a process for the production of a protein according to the invention characterized in that it is produced by means of a DNA sequence encoding the amino acid sequence of SEQ ID NO 2 by genetic engineering in a manner known per se.
  • The process according to the invention can be characterized in that the production is carried out by means of a plasmid according to the invention.
  • Further, the process according to the invention can be characterized in that the host is selected from the group consisting of bacteria, fungi, yeast, plant cells, insect cells, mammalian cells and cell cultures (heterologous expression).
  • Further, the process according to the invention can be characterized in that Escherichia coli is used as host.
  • Still another embodiment of the invention concerns the use of a protein according to the invention for testing and recovering inhibitory substances which inhibit activities of said protein.
  • Still another embodiment of the invention concerns a test system for testing the catalytic activity of a protein according to the invention or obtained according to the process according to the invention, wherein the testing system contains or comprises trypanothione, trypanothione reductase, a tryparedoxin peroxidase, a tryparedoxin and, in addition, a hydroperoxide as indicator enzyme, mediator and substrate, respectively.
  • Finally, another embodiment of the invention concerns a pharmaceutical preparation having a trypanocidal activity and comprising an inhibitory substance inhibiting the catalytic activity of a protein according to the invention or of a protein which can be obtained according to the process according to the invention.
  • The pharmaceutical composition according to the invention can be characterized in that it can be obtained by a use according to the invention and by using a test system according to the invention.
  • The invention is now described in greater detail by means of figures and examples.
  • FIG. 1 Flux of reducing equivalents from NADPH to hydroperoxide in C. fasciculata. TR=trypanothione reductase; T(SH)2=trypanothione; TS2=trypanothione disulphide; TXN=tryparedoxin; TXNPx=tryparedoxin peroxidase; ROOH=hydroperoxide.
  • FIG. 2 Nucleotide sequence and deduced amino acid sequences of the PCR product used to screen a genomic library for inserts containing the tryparedoxin I gene. Partial sequences confirmed by protein sequence analysis are underlined and the sequences corresponding to the primers used to obtain the PCR product are double underlined.
  • FIG. 3 Nucleotide and amino acid sequences of tryparedoxin II isolated from a C. fasciculata genomic library. The start and stop codons are in bold. The position of the Pvu II site from which one third of the gene at the 5′ end of the open reading frame was determined is double underlined. The WCPPC thioredoxin-like motif is underlined.
  • FIG. 4 Components of the trypanothione-mediated hydroperoxide metabolising system from C. fasciculata in silver-stained SDS-PAGE (8-25%). Lane 2, extract of disrupted cells; lane 3, trypanothione reductase, lane 4, tryparedoxin peroxidase and lane 5, tryparedoxin I. Lanes 1 and 6, molecular weight standards.
  • FIG. 5 Molecular mass determination by MALDI-TOF of pure tryparedoxin I from C. fasciculata (trace A), tryparedoxin I exposed to iodoacetamide (trace B), T(SH)2-reduced tryparedoxin I derivatized with iodoacetamide (trace C) and with iodoacetamide plus N-ethylmaleimide (trace D). The mass increments shown in traces C and D correspond to the addition of one carboxyamidomethyl residue (observed 54 Da, theoretical 57 Da) and one carboxyamidomethyl plus one N-ethylsuccinimide residue (observed 185 Da, theoretical 182 Da), respectively.
  • FIG. 6 NADPH-dependent hydroperoxide metabolism reconstituted from components isolated from C. fasciculata. Peroxidase activity depends on both isolated proteins, tryparedoxin I (TXN I) (A) and tryparedoxin peroxidase (TXNPx) (B), as well as T(SH)2 (E) and trypanothione reductase (TR) (F). The comparatively high activity in (F) observed immediately after the addition of TR is due to the accumulation of its substrate, TS2. Note that the reaction is comparably fast with H2O2 (D) and t-bOOH (C). The tests were performed at 27° C. with 0.1 mM NADPH, 16.5 μg/ml tryparedoxin peroxidase, 12 μg/ml tryparedoxin I, 45 μM T(SH)2, 45 μM hydroperoxide and 0.4 U/ml TR. NADPH consumption was measured photometrically at 340 nm.
  • FIG. 7 Sequence alignment of the peptide fragments of tryparedoxin I with thioredoxin-like protein of Caenorhabditis elegans (TLP/CE).Tryparedoxin I was digested with trypsin (Tryp) or endoproteinase Glu-C (Glu-C). Asterisks denote conserved residues.
  • FIG. 8 Tryparedoxin II containing a His tag specific activity determined in the supernatants of sonicated E. coli BL21(DE3)pET24a cells (black square) and E. coli BL2 I (DE3)pET/TXN II H6 cells (black circle). Gene expression induction by isopropyl-β-D-thiogalactopyranoside addition is indicated by an arrow.
  • FIG. 9 Western blot analysis of expressed tryparedoxin II containing a His tag SDS-PAGE was done under reducing conditions in 8-25% gradient gels on a Pharmacia Pliast System and the samples were electroblotted onto a PVDF membrane using a Pharmacia Phast System. Whole rabbit serum (1:500 dilution) containing antibodies raised against pure C. fasciculata tryparedoxin I was used as primary antibody and anti-rabbit goat antibodies (Sigma) as secondary antibody. Lane 1, supernatant of E. coli BL21(DE3) pET/TXN II H6 cells 6 h after induction; lane 2, purified recombinant tryparedoxin II; lane 3, authentic tryparedoxin I from C. fasciculata.
  • FIG. 10 Tryparedoxin II specific activity determined in the supernatants of sonicated E. coli BL21(DE3)pET24a cells (black square) and E. coli BL-21(DE3)pET/TXN II cells (black rhomb). Gene expression induction by isopropyl-β-D-thiogalactopyranoside addition is indicated by an arrow.
  • FIG. 11 Western blot analysis of expressed tryparedoxin II. SDS-PAGE was done under reducing conditions in 8-25% gradient gels on a Pharmacia Phast System and the samples were electroblotted onto a PVDF membrane using a Pharmacia Phast System. Whole rabbit serum (1:500 dilution) containing antibodies raised against pure C. fasciculata tryparedoxin I was used as primary antibody and anti-rabbit goat antibodies (Sigma) as secondary antibody. Lane 1, authentic tryparedoxin I from C. fasciculata; lane 2, supernatant of E. coli BL21(DE3) pET/TXN II cells 6 h after induction.
  • FIG. 12 SDS-PAGE of expressed tryparedoxin II containing a His tag. SDS-PAGE was done under reducing conditions in 8-25% gradient gels on a Pharmacia Phast System and the gels were stained for protein with silver according to the manufacturers' recommendations. Lane 2, supernatant of E. coli BL21(DE3) pET24a cells after 6h induction; lane 2, supernatant of E. coli BL21(DE3) pET/TXN II H6 cells 6 h after induction; lane 3, purified recombinant tryparedoxin II; lane 4, authentic tryparedoxin I from C. fasciculata. Lanes 1 and 6, molecular weight standards.
    • EXAMPLE 1 Isolation of Tryparedoxin from C. fasciculata
  • C. fasciculata was cultivated in a 100 I fermenter as described (Shim and Fairlamb, 1988). The cells were harvested in the late log phase, suspended in 50 mM sodium phosphate pH 5.8 (buffer B) containing 0.1 mM PMSF, then frozen and thawed twice to complete cell disruption. Cell debris was removed by centrifugation at 25,000×g for 30 min and the supernatant was applied on an S-Sepharose column pre-equilibrated with buffer B. Tryparedoxin peroxidase eluted at 150 mM NaCl in buffer B and was directly loaded on a hydroxyapatite (BioRad, USA) column pre-equilibrated with 10 mM sodium phosphate pH 6.8. Tryparedoxin peroxidase was eluted stepwise with 0.4 M potassium phosphate pH 6.8. The protein was extensively dialyzed against 20 mM Tris pH 7.6 (buffer C) and purified to homogeneity on a Resource Q column, eluting at 0.1 M NaCl in buffer C. The flow-through of the S-Sepharose column containing trypanothione reductase and tryparedoxin can be used to measure the enzymatic activity of tryparedoxin peroxidase (see example 2). The flow-through of the S-Sepharose column, containing trypanothione reductase and tryparedoxin, was adjusted to pH 7.2 with 1 M NaOH. The extract was adjusted to 3% (w/v) streptomycin sulphate, brought to 50%. ammonium sulphate saturation, and centrifuged for 10 min at 11,000×g. The supernatant was adjusted to 80% ammonium sulphate saturation and recentrifuged. The pellet was dissolved in, then dialyzed extensively, against 20 mM bis-Tris propane pH 7.2 containing 1 mM EDTA and 1 mM DTT (buffer D). The enzyme extract was loaded on a DEAE-Sepharose column and eluted with a linear gradient of 0.4 M KCl in buffer D. The sample eluting at 80-120 mM KCl was concentrated by ultrafiltration (Omegacell, Filtron, Germany), washed with 20 mM potassium phosphate pH 7.2 containing 1 mM EDTA and 1 mM DTT (buffer E) and loaded on a 2′5′ADP-Sepharose 4B column. Trypanothione reductase was eluted with 5 mM NADP in buffer E and purified to homogeneity on a Sephacryl S-200 column. The unbound fraction was concentrated by ultrafiltration and fractionated on an Ultrogel AcA54 (LKB, Sweden) gel filtration column in 50 mM Hepes pH 7.6 containing 150 mM NaCl, 1 mM EDTA and 1 mM DTT to yield homogeneous tryparedoxin. The authentic tryparedoxin, thus isolated, is termed tryparedoxin I (TXN I). The overall yields of the final purification scheme are shown in Table 1.
    TABLE 1
    Yields and purification factors during the isolation of tryparedoxin I.
    Volume Activity Protein Yield Purification
    (ml) (U) (mg) U/mg (%) factor
    Cell extract 180 386 3322 1e+10 (100) (1.0)
    (NH4)2SO4 86 134 1728  35 0.7
    precipitation
    DEAE- 270 136 176  36 6.4
    Sepharose
    Ultrogel 13 51 22  13 20.2
    AcA54
  • Based on the purification factors yielding homogeneous products the minimum concentrations of tryparedoxin and tryparedoxin peroxidase in the starting material were estimated to amount to 5% and 6% of the total soluble protein, respectively. The homogeneity and approximate molecular masses of the purified proteins are shown in FIG. 4. The apparent subunit masses deduced by SDS-PAGE (about 16000) were compatible with those obtained by MALDI, 16393±10 (FIG. 5).
  • Analyses of the spectral properties of the two proteins confirmed the absence of any chromophoric cofactors absorbing in the visible region.
    • EXAMPLE 2 Determination of Tryparedoxin Activity
  • In essence, the activity of tryparedoxin activity is measured by coupling the catalytic reduction of hydroperoxide mediated by tryparedoxin peroxidase to NADPH consumption by means of trypanothione and trypanothione reductase. For example, an assay sample may contain 0.1 mM NADPH in 50 mM Hepes pH 7.6, 1 mM EDTA, 50 M H2O2 or t-butyl hydroperoxide (t-bOOH), 45 M T(SH)2, 16.5 μg/ml tryparedoxin peroxidase and 0.34 U trypanothione reductase and an unknown amount of tryparedoxin. Unless otherwise stated, the reaction is started with the addition of the hydroperoxide. Dihydro-trypanothione is obtained by chemical reduction of TS2 (Bachem, Switzerland) as described (Fairlamb et al., 1986). t-BOOH may be replaced by other hydroperoxides, such as H2O2, linoleic acid hydroperoxide or phosphatidylcholine hydroperoxide.
  • FIG. 6 demonstrates that trypanothione reductase, T(SH)2, tryparedoxin and tryparedoxin peroxidase are indispensable for the efficient reduction of H2O2 or alkyl hydroperoxides by NADPH. The T(SH)2-mediated “NADPH peroxidase activity” of C. fasciculata is thus achieved by the concerted action of three distinct proteins; the well characterized trypanothione reductase (Bailey et al., 1993), tryparedoxin and tryparedoxin peroxidase.
    • EXAMPLE 3 Characterisation of Tryparedoxin I by Partial Proteins Sequencing
  • Since the N-terminus of tryparedoxin I was blocked, the protein was digested with either bovine trypsin or endoproteinase Glu-C from Staphylococcus aureus (both sequencing grade, Promega) according to Stone and Williams (1993). The peptides were separated by HPLC (Applied Biosystems 172A) on an Aquapore OD-300 RP-18 column. Automated Edman degradation was performed with an Applied Biosystems, Inc. sequencer with an on-line C-18 reverse phase HPLC. Database searches were performed with the BLAST and FASTA programs. Peptides were aligned with the Bestfit program, Genetics Computer Group (GCG), Madison, Wis., USA.
  • Seven fragments could be sequenced and could be aligned to a thioredoxin-like protein of C. elegans (FIG. 7).
    • EXAMPLE 4 Use of Sequenced Fragments of Tryparedoxin I to Elucidate the Encoding DNA
  • Cells culture and DNA extraction: C. fasciculata (HS6) was grown as described by Shim and Fairlamb (1988). The cells were harvested by centrifugation for 15 min at 7000 rpm, washed twice with saline solution (0.9% NaCl) and resuspended in 5 ml buffer (50 mM TrisHCl, 100 mM EDTA, 15 mM NaCl, 0.5% SDS, 100 μg ml−1 Proteinase K, pH 8.0). Resuspended cells were preincubated at 50° C. for 40 min. The genomic DNA was extracted twice with equivalent volumes of phenol (incubation: 60° C. for 45 min; centrifugation: 20 min, 4500 rpm) followed by phenol:chloroform:isoamyl alcohol (25:24:1) and chloroform:isoamyl alcohol extraction (24:1). Genomic DNA was precipitated with sodium acetate and ethanol.
  • Primers, hybridization probes and sequence analysis: Based on the peptide sequences of tryparedoxin I (Nogoceke et al., 1997) degenerate oligodeoxyribonucleotides were synthesized. Polymerase chain reaction (PCR) amplification was performed using the GeneAmp PCR Core kit (Perkin Elmer) using 0.2 μg of C. fasciculata genomic DNA as template, 5 μl of 10× reaction buffer, 3 μl 25 mM MgCl2, 1 μl of each 10 μM dNTP, 100 pmol of each primer and 0.25 U Taq polymerase. An annealing temperature of 52° C. was used. The PCR product was analysed by agarose gels and purified using the QIAquick PCR purification kit (QIAGEN Inc.). Sequencing was performed on a 373A DNA Sequencer (Applied Biosystems) using the PRISM Ready Reaction DyeDeoxy Terminator Sequencing Kit (1550V, 19 mA, 30 W, 42° C.). When used as a hybridization probe the PCR product was labelled with digoxigenin using the DIG DNA Labeling Kit (Boehringer Mannheim) according to the instructions provided by the supplier.
  • Library construction and screening procedure: The genomic DNA was partially digested for 5-30 min with a ratio unit Sau3A /μg DNA of 0.005. The efficiency of the digestion was monitored by electrophoresis on agarose gels. Proteins were removed from the DNA using StrataClean Resin (Stratagene). The Sau3A sites were partially refilled with dATP and dGTP and Klenow fragment. The genomic DNA was ligated into Lambda GEM-11 Xho I half site arms (Promega) at a molar ratio of DNA to genomic DNA (average size 15 kb) of 1:0.7. The ligated DNA was packaged using the Packagene Lambda DNA Packaging System (Promega) according to the suppliers' instructions. The phages were used to infect the E. coli host strain LE392 (Promega) according to the standard protocol. 5.1×103 pfu of the genomic library were plated on agar. The plaques were transferred to 9 cm diameter Biodyne-A nylon membranes and screened with the DIG-labelled PCR probes following the instructions provided by the supplier but using a hybridization temperature of 54 C. DIG labelled nucleic acids were detected calorimetrically with the DIG Nucleic Acid Detection Kit (Boehringer Mannheim). Positive clones were rescreened, amplified and suspended in SM buffer. The phages were precipitated by PEG 8000 and purified in CsCl gradients. The isolated DNA was used for restriction analyses (Sac I, EcoR I, BamH I, Xho I, Nco I) or as template for PCR reactions. The digestion products were eluted from agarose gels and ligated into pBluescript II KS (±) phagemids (Stratagene) or pET24d(+) vector (Novagen). The ligated DNA was used to transform E. coli LE392. Transformed cells were selected by ampicillin (pBluescript II KS (±) phagemid) or kanamycin (pET24d(+) vector) resistance, plasmids were purified using QIAprep Spin Plasmid Kit (Qiagen Inc.) and analyzed by restriction enzyme digestion and sequencing.
  • Isolation and sequencing of tryparedoxin genes from C. fasciculata: Sequenced peptide fragments obtained from isolated tryparedoxin I of C. fasciculata (Nogoceke et al., 1997) could be aligned along the established deduced amino acid sequence of a thioredoxin-like protein of Caenorhabditis elegans. This enabled appropriate degenerate PCR primers to be designed for the generation of a PCR product from the C. fasciculata genomic DNA. This PCR product, which coded for approximately the 50% of tryparedoxin I (FIG. 2), was subsequently used to screen a genomic library for inserts containing the full length. DNA encoding tryparedoxin I. A clone containing a 22 kb insert with the presumed tryparedoxin I gene was isolated. The DNA was digested with the restriction enzyme Sac I to separate the phage arms from the insert and with the restriction enzyme Nco I. A southern blot was performed and a fragment of 6 kb hybridized with the labelled PCR product. The fragment was subcloned into the pET24d(+) vector (Novagen). Subsequent digestion of the cloned fragment with the restriction enzyme Pvu II led to the isolation and cloning of a 1 kb fragment. When this fragment was sequenced it contained only one third of the gene coding for tryparedoxin at the 5′ end of the open reading frame (FIG. 3). The DNA sequence thus obtained was in full agreement with the peptide sequence derived from the isolated tryparedoxin I.
    • EXAMPLE 5 Isolation of a New Tryparedoxin Gene (TXN II)
  • New primers were designed using the information obtained in example 4 and the complete gene was sequenced directly from the 6 kb fragment. The previously obtained PCR product is about 60% identical in its amino acid sequence to the correponding region of the isolated gene. The full length encoding DNA and the deduced amino acid sequence are shown in FIG. 3. The gene encodes for a protein with a molecular mass of 17000, while the molecular mass of natural tryparedoxin I isolated from C. fasciculata is 16393±10 (Nogoceke et al.,1997).
    • EXAMPLE 6 Heterologous Expression of Tryparedoxin II in Escherichia coli
  • The tryparedoxin gene contained in the cloned 6 kb fragment was amplified by PCR with a forward primer A (5′-TCGTGATTCCGTTCCGCATATGTCAGGGC-3′) that contains an Nde I site and overlaps the 5′ end of the coding sequence, and a reverse primer B. (5′-GCAACTCAATCGCTCCCCTCGAGCTTCTTGGCCTCC-3′) which overlaps the 3′ end of the coding sequence and contains an Xho I site. Consequently a leucine and a glutamate residue are added, the stop codon is deleted and the protein will contain 6 histidine residues at its carboxyl-terminal end. Amplification was performed as above but using the Expand High Fidelity polymerase mixture and buffer (Boehringer Mannheim) at an annealing temperature of 50° C. with the extension temperature being increased in 10 sec increments per cycle during cycles 10-20. The amplified coding region was digested with Nde I and Xho I and ligated to a pET24a(+) vector (Novagen) treated with the same enzymes and dephosphorylated. The resulting plasmid (pET/TXN II H6) was used to transform E. coli BL21(DE3). Transformed cells were selected by kanamycin resistance, the plasmids purified and sequenced.
  • The same procedure, but using a reverse primer C (5′- CAGCAACTCAATGGATCC TCATTACTTCTTGGCC-3′) instead of reverse primer B, was used to express tryparedoxin II with no changes at the carboxyl-terminal end. In this case the reverse primer contained an extra stop codon and a BamH I site at the 5′-end of the extra stop codon, with the digestions for the cloning step being performed with Nde I and BamH I. The resulting plasmid was called pET/17 II and was used to transform E. coli BL21(DE3). Transformed cells were selected by kanamycin resistance, the plasmids purified and sequenced.
  • E. coli BL21(DE3) pET/TXN IIH6 were grown to A600 of 0.9-1.0 at 25° C. and 180 rpm in LB medium with 30 μg kanamycin/ml, then expression of the tryparedoxin II gene was induced with 1 mM isopropyl-D-thiogalactopyranoside. E. coli BL21(DE3) containing the pET24a plasmid was grown in the same way. Samples taken at, different times were centrifuged, resuspended in 50 mM Tris-HCl pH 8.0, 1 mM EDTA buffer, sonicated and centrifuged. Enzyme activity was determined as in Nogoceke et al. (1997); protein concentration was determined using Coomassie Brilliant Blue-G reagent (BioRad) with bovine serum albumin as standard. After induction of the transformed bacteria, a marked increase in tryparedoxin activity was detected in supernatants of sonicated cells. Activity increased to a maximum 6 hours after induction and no activity was found in the control (FIG. 8). Induction resulted in the accumulation of a new protein with an apparent molecular mass of 18000, which was recognised by the anti-tryparedoxin antibodies raised against pure C. fasciculata tryparedoxin I (FIG. 9).
  • E. coli BL21(DE3) pET/TXN II were grown to A600 of 0.9-1.0 at 25° C. and 180 rpm in LB medium with 30 μg kanamycin/ml, then expression of the tryparedoxin II gene was induced with 1 mM isopropyl-D-thiogalactopyranoside. E. coli BL21(DE3) containing the pET24a plasmid was grown in the same way. Samples taken at different times were centrifuged, resuspended in 50 mM Tris-HCl pH 8.0, 1 mM EDTA buffer, sonicated and centrifuged. Enzyme activity was determined as in Nogoceke et al. (1997); protein concentration was determined using Coomassie Brilliant Blue-G reagent (BioRad) with bovine serum albumin as standard. After induction of the transformed bacteria, a marked increase in tryparedoxin activity was detected in supernatants of sonicated cells. Activity increased to a maximum 6 hours after induction and no activity was found in the control (FIG. 10). Induction resulted in the accumulation of a new protein with an apparent molecular mass of 18000, which was recognised by the anti-tryparedoxin antibodies raised against pure C. fasciculata tryparedoxin I (FIG. 11)
    • EXAMPLE 7 Purification and Characterization of Recombinant Tryparedoxin II
  • E. coli BL21(DE3) pET/TXN II H6 was grown at 25° C. and 180 rpm in LB medium with 30 μg kanamycin/ml to A600 of 0.9-1.0, then expression of the tryparedoxin II gene was induced with 1 mM isopropyl-D-thiogalactopyranoside. After 6 h the culture was centrifuged and either stored at −20° C. or the cells were resuspended in 0.05 culture volumes of binding buffer (5 mM imidazole, 500 mM NaCl and 20 mM Tris-HCl pH 7.9). The cell suspension was sonicated on ice and centrifuged for 40 min at 4° C., 13000 rpm. The supernatant was applied to a His Bind resin (Novagen) column charged with Ni2+ and equilibrated with binding buffer, at a flow rate of about 10 column volumes per hour. The column was washed with 10 volumes of binding buffer and 6 volumes of 500 mM NaCl, 20 mM Tris-HCl pH 7.9 buffer containing 100 mM imidazole. Tryparedoxin eluted in the buffer containing 500 mM imidazole. Active fractions were pooled and immediately dialysed against 50 mM Tris-HCl pH 7.6 buffer containing 1 mM DTT and 1 mM EDTA. Tryparedoxin II eluted at 500 mM imidazole and was shown to be pure by SDS-PAGE and subsequent silver staining (FIG. 12). N-terminal sequencing of this protein showed the initial methionine to be missing and allowed us to confirm the first 20 amino acids. The expressed tryparedoxin II showed a molecular mass of about 18000 in SDS-PAGE (FIG. 12 ), being slightly bigger than the authentic tryparedoxin I. The difference in the molecular mass between the recombinant and authentic tryparedoxin peroxidase corresponded mainly to the additional amino acids (leucine, glutamate and 6 histidine residues) added at the C-terminal end of the recombinant enzyme.
  • The purified recombinant enzyme had a specific activity of 7.7 U/mg compared to 2.3 U/mg for the authentic enzyme.
    • EXAMPLE 8 Inhibition Studies
  • The test system described in example 2 is easily adapted to screen compounds for specific inhibition of tryparedoxin I. As an example the inhibition of tryparedoxin peroxidase by S-modifying agents such as N-ethylmaleimide (NEM), iodoacetamide (IAM) and phenylarsine oxide (PAO) is described (Table 2). Tryparedoxin was preincubated in 50 mM Hepes, 1 mM EDTA, pH 7.6 with or without presumed reducing substrate (T(SH)2), then reacted with inhibitors and activity was checked at 22° C. essentially as described in example 2. Changes in molecular mass were determined by MALDI-TOF-MS (FIG. 5).
    TABLE 2
    Derivatisation scheme of tryparedoxin.
    residual
    Protein Pretreatment Derivatisation mass incrementb activity [%]
    tryparedoxin 1.16 mM T(SH)2; — — −100
    (9.5 μM) 15 min at 22° C.
    none
    a 3 mM IAM; 30 min at 22° C. 4 ± 3 (0)  83 ± 5
    1.16 mM T(SH)2; 3 mM IAM; 30 min at 22° C. 57 ± 3 (57)c  0 ± 5
    15 min at 22° C. 3 mM NEM; 30 min at 22° C. 251 ± 3 (250)d 24 ± 5
    3 mM PAO; 30 min at 22° C. 154 ± 3 (152)c n.d.e

    astored under non-reducing conditions

    bvalues in brackets represent predicted mass increments

    cone molecule of derivatising agent

    dtwo molecules of derivatising agent

    einhibition reversible; activity regained within the timescale of the test
  • Tryparedoxin was preincubated in 50 mM Hepes, 1 mM EDTA, pH 7.6 with presumed reducing substrates, then reacted with iodoacetamide (IAM), NEM or phenylarsine oxide (PAO). Changes in molecular mass were determined my MALDI-TOF-MS. Residual activity was measured at 22° C. using 1 mM T(SH)2 with 1.0 μM tryparedoxin peroxidase and 0.6 μM tryparedoxin.
  • The disclosure comprises also that of EP 96 120 015.1, the entire disclosure of which is incorporated herein by reference.
  • References
    • Bailey, S., Smith, K., Fairlamb, A. H. and Hunter, W. H. (1993) Substrate interactions between trypanothione reductase and N1-glutathionylspermidine disulphide at 0.28-nm resolution. Eur. J. Biochem. 213, 67-75.
    • Carnieni, E. G. S., Moreno, S. N. J. and Docampo, R. (1993) Trypanothicne-dependent peroxide metabolism in Trypanosoma cruzi different stages. Mol. Biochem. Parasitol. 61, 79-86.
    • Chance, B., Sies, H. and Boveris, A. (1979) Hydroperoxide metabolism in mammalian organs. Physiol. Rev. 59, 527-605.
    • Dalziel, K. (1957) Initial steady state velocities in the evaluation of enzyme-coenzyme-substrate reaction mechanisms. Acta Chem. Scand. 11, 1706-1723.
    • Docampo, R. (1990) Sensitivity of parasites to free radical damage by antiparasitic drugs. Chem. Biol. Interactions 73, 1-27.
    • Fairlamb, A. H. (1996) Pathways to drug discovery. The Biochemist 18 (February/March), 11-16.
    • Fairlamb, A. H., Blackburn, P., Ulrich, P., Chait, B. T. and Cerami, A. (1985) Trypanothione: A novel bis (glutathionyl) spermidine cofactor for glutathione reductase in trypanosomatids. Science 227, 1485-1487.
    • Fairlamb, A. H. and Cerami, A. (1992) Metabolism and functions of trypanothione in the kinetoplastida. Annu. Rev. Microbiol. 46, 695-729.
    • Fairlamb, A. H., Henderson, G. B. and Cerami, A. (1986) The biosynthesis of trypanothione and N1-glutathionylspermidine in Crithidia fasciculata. Mol. Biochem. Parasitol. 21, 247-257.
    • Field, H. and Field, M. C. (1997) Tandem duplication of rab genes followed by sequence divergence and acquisition of distinct functions in Trypanosoma brucei. J. Biol. Chem. 272,10498-10505.
    • Flohe, L. (1989) The selenoprotein glutathione peroxidase. In: Glutathione—chemical, biochemical, and medical aspects. D. Dolphin, R. Poulson, and O. Avramovic, eds. (New York, USA: J. Wiley and Sons, Inc.) pp. 643-731.
    • Flohe, L., Loschen, G., Guinzler, W. A. and Eichele, E. (1972) Glutathione peroxidase. V. The kinetic mechanism. Hoppe-Seyler's Z. Physiol. Chem. 353, 987-999.
    • Henderson, G. B., Fairlamb, A. H. and Cerami, A. (1987) Trypanothione dependent peroxide metabolism in Crithidia fasciculata and Trypanosoma brucei. Mol. Biochem. Parasitol. 24, 3945.
    • Jacoby, E. M., Schlichting, I., Lantwin, C. B., Kabsch, W., and Krauth-Siegel, R. L. (1996) Crystal structure of the Trypanosoma cruzi trypanothione reductase-mepacrine complex. Proteins 24, 73-80.
    • LeTrant, N., Meshnick, S. R., Kitchener, K., Eaton, J. W. and Cerami, A. (1983) Iron-containing superoxide dismutase from Crithidia fasciculata. J. Biol. Chem. 258, 125-130.
    • Nogoceke, E. Gommel, D. U., Kieβ, M., Kalisz, H. M. and Flohe, L. (1997) A unique cascade of oxidoreductases catalyses trypanothione-dependent peroxide metabolism in Crithidia fasciculata. Biol. Chem., 378, 827-836.
    • Penketh, P. G., Kennedy, W. P. K., Patton, C. L. and Sartorelli, A. C. (1987) Trypanosomatid hydrogen peroxidase metabolism. FEBS Lett. 221, 427-431.
    • Penketh, P. G. and Klein, R. A. (1986) Hydrogen peroxide metabolism in Trypanosoma brucei.Mol. Biochem. Parasitol. 20, 111-121.
    • Risse, H. J. (1993) Afrikanische Trypanosomen—Meister im Austricksen des Immun-systems In: Extremophile. K. Hausmann, and B. P. Kremer, eds. (Weinheim, Germany: VCH) pp. 361-380.
    • Shim, H. and Fairlamb, A. H. (1988) Levels of polyamines, glutathione, and glutathione-spermidine conjugates during growth of the insect trypanosomatid C. fasciculata. J. Gen. Microbiol. 134, 807-817.
    • Stone, K. L. and Williams, K. R. (1993) Enzymatic digestion of proteins and HPLC peptide isolation. In: A practical guide to protein and peptide purification for microsequencing, 2nd ed. P. Matsudaira, ed. (London, England: Academic Press Inc.) pp.45-69.
    • Tschudi, C., Young A. S., Ruben, L., Patton, C. L. and Richards F. F. (1985) Proc. Nat. Acad.Sci.USA 82, 3998-4002
    • World Health Organization (1996) Fighting disease, fostering development. World Health Report 1996 (Geneva, Switzerland: WHO).

Claims (16)

1-28. (canceled)
29. An isolated tryparedoxin (TXN) protein, said TXN protein having an activity which transfers reductive equivalents of trypanothione (T(SH)2) to a peroxiredoxin, said TXN protein having a molecular weight of between 15 kDa to 19 kDa as determined by mass spectrometry, and said protein having a WCPPC motif.
30. The protein of claim 29, wherein said TXN protein is prepared by genetic engineering.
31. The protein of claim 30, wherein said TXN protein is prepared by expression of a plasmid comprising a nucleic acid molecule encoding said protein.
32. The protein of claim 29, wherein said TXN protein is prepared or isolated from a species of the family Trypanosomatidae.
33. The protein of claim 29, wherein said TXN protein catalyzes the reduction of a protein disulfide by T(SH)2.
34. An isolated polypeptide comprising an amino acid sequence that is at least 70 percent homologous to the amino acid sequence of SEQ ID NO: 4 or 6, wherein the polypeptide has tryparedoxin (TXN) activity.
35. The polypeptide of claim 34 comprising the amino acid sequence set forth in SEQ ID NO: 4.
36. The polypeptide of claim 34 comprising the amino acid sequence set forth in SEQ ID NO: 6.
37. The polypeptide of claim 34 comprising a portion of the amino acid sequence of SEQ ID NO: 4, wherein said portion retains a WCPPC motif and retains TXN activity.
38. The polypeptide of claim 34 comprising a portion of the amino acid sequence of SEQ ID NO: 6, wherein said portion retains a WCPPC motif and retains TXN activity.
39. The polypeptide of claim 34 comprising at least 120 amino acids of SEQ ID NO: 6.
40. The polypeptide of any of claims 34-39, wherein said polypeptide is prepared or isolated from a species of the family Trypanosomatidae.
41. The polypeptide of any of claims 34-39, wherein said polypeptide catalyzes the reduction of a protein disulfide by T(SH)2.
42. The polypeptide of claim 31 encoded by the nucleic acid molecule of SEQ ID NO: 5.
43. The polypeptide of claim 31 encoded by the nucleic acid molecule of SEQ ID NO: 7.
US10/962,760 1996-12-12 2004-10-12 Tryparedoxin, expression plasmid, process of preparation, method of use, test kit and pharmaceutical composition Abandoned US20050143559A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US10/962,760 US20050143559A1 (en) 1996-12-12 2004-10-12 Tryparedoxin, expression plasmid, process of preparation, method of use, test kit and pharmaceutical composition

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
EP96120015 1996-12-12
EP96120015.1 1996-12-12
PCT/EP1997/006983 WO1998026051A2 (en) 1996-12-12 1997-12-12 Tryparedoxin, expression plasmid, process of production, use, test system and pharmaceutical preparation
US09/330,914 US6432671B1 (en) 1996-12-12 1999-06-11 Tryparedoxin, expression plasmid, process of production, method of use, test kit, and pharmaceutical composition
US10/193,795 US20030082202A1 (en) 1996-12-12 2002-07-12 Tryparedoxin, expression plasmid, process of production, method of use, test kit, and pharmaceutical composition
US10/962,760 US20050143559A1 (en) 1996-12-12 2004-10-12 Tryparedoxin, expression plasmid, process of preparation, method of use, test kit and pharmaceutical composition

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10/193,795 Division US20030082202A1 (en) 1996-12-12 2002-07-12 Tryparedoxin, expression plasmid, process of production, method of use, test kit, and pharmaceutical composition

Publications (1)

Publication Number Publication Date
US20050143559A1 true US20050143559A1 (en) 2005-06-30

Family

ID=8223490

Family Applications (3)

Application Number Title Priority Date Filing Date
US09/330,914 Expired - Fee Related US6432671B1 (en) 1996-12-12 1999-06-11 Tryparedoxin, expression plasmid, process of production, method of use, test kit, and pharmaceutical composition
US10/193,795 Abandoned US20030082202A1 (en) 1996-12-12 2002-07-12 Tryparedoxin, expression plasmid, process of production, method of use, test kit, and pharmaceutical composition
US10/962,760 Abandoned US20050143559A1 (en) 1996-12-12 2004-10-12 Tryparedoxin, expression plasmid, process of preparation, method of use, test kit and pharmaceutical composition

Family Applications Before (2)

Application Number Title Priority Date Filing Date
US09/330,914 Expired - Fee Related US6432671B1 (en) 1996-12-12 1999-06-11 Tryparedoxin, expression plasmid, process of production, method of use, test kit, and pharmaceutical composition
US10/193,795 Abandoned US20030082202A1 (en) 1996-12-12 2002-07-12 Tryparedoxin, expression plasmid, process of production, method of use, test kit, and pharmaceutical composition

Country Status (10)

Country Link
US (3) US6432671B1 (en)
EP (1) EP0944718A2 (en)
JP (1) JP2001505773A (en)
KR (1) KR20000069395A (en)
AU (1) AU746917B2 (en)
BR (1) BR9714010A (en)
CA (1) CA2275175A1 (en)
IL (1) IL130272A0 (en)
NZ (1) NZ335968A (en)
WO (1) WO1998026051A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006081222A3 (en) * 2005-01-25 2007-02-22 Compass Genetics Llc Isothermal dna amplification

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20000069395A (en) * 1996-12-12 2000-11-25 프로헤 레오폴드 Tryparedoxin, expression plasmid, process of production, use, test system and pharmaceutical preparation
WO2003087312A2 (en) * 2002-04-08 2003-10-23 The Johns Hopkins University Inhibition of tumor growth via peroxiredoxin 3
US7303877B2 (en) * 2003-03-31 2007-12-04 Novozymes, Inc. Methods for producing biological substances in enzyme-deficient mutants of Aspergillus

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4942170A (en) * 1988-05-27 1990-07-17 The Rockefeller University 2-(substituted methylidene)-N-[3-[piperidin-1-yl]propyl]hydrazine carboximidamides useful as antiparasitics
KR20000069395A (en) * 1996-12-12 2000-11-25 프로헤 레오폴드 Tryparedoxin, expression plasmid, process of production, use, test system and pharmaceutical preparation

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006081222A3 (en) * 2005-01-25 2007-02-22 Compass Genetics Llc Isothermal dna amplification

Also Published As

Publication number Publication date
EP0944718A2 (en) 1999-09-29
JP2001505773A (en) 2001-05-08
NZ335968A (en) 2000-12-22
WO1998026051A2 (en) 1998-06-18
AU5856398A (en) 1998-07-03
AU746917B2 (en) 2002-05-02
WO1998026051A3 (en) 1998-11-19
US6432671B1 (en) 2002-08-13
KR20000069395A (en) 2000-11-25
US20030082202A1 (en) 2003-05-01
IL130272A0 (en) 2000-06-01
BR9714010A (en) 2000-05-09
CA2275175A1 (en) 1998-06-18

Similar Documents

Publication Publication Date Title
Moskovitz et al. Cloning the expression of a mammalian gene involved in the reduction of methionine sulfoxide residues in proteins.
Bueno et al. Peroxisomal copper, zinc superoxide dismutase (characterization of the isoenzyme from watermelon cotyledons)
Nogoceke et al. A unique cascade of oxidoreductases catalyses trypanothione-mediated peroxide metabolism in Crithidia fasciculata
Dailey et al. Human protoporphyrinogen oxidase: expression, purification, and characterization of the cloned enzyme
Bugos et al. Molecular cloning of violaxanthin de-epoxidase from romaine lettuce and expression in Escherichia coli.
Tetaud et al. Molecular characterisation of mitochondrial and cytosolic trypanothione-dependent tryparedoxin peroxidases in Trypanosoma brucei
Cheong et al. Molecular cloning, expression, and functional characterization of a 2Cys-peroxiredoxin in Chinese cabbage
Scalla et al. Cloning and characterization of a glutathione S‐transferase induced by a herbicide safener in barley (Hordeum vulgare)
Kong et al. Non-essentiality of cysteine and histidine residues for the activity of human class pi glutathione S-transferase
US7745693B2 (en) Inhibitors of plant peptide deformylase for use as broad-spectrum herbicides and methods for identifying the same
US6432671B1 (en) Tryparedoxin, expression plasmid, process of production, method of use, test kit, and pharmaceutical composition
KR100782607B1 (en) Beta,beta-carotene 15,15'-dioxygenases
WO1998026051A9 (en) Tryparedoxin, expression plasmid, process of production, use, test system and pharmaceutical preparation
Steinert et al. Permutation of the active site motif of tryparedoxin 2
Li et al. Effects of N-terminal deletions on 1-aminocyclopropane-1-carboxylate synthase activity
AU731699B2 (en) Tryparedoxin peroxidase
JP3355368B2 (en) Plasmid vector containing cDNA encoding plant-derived epoxide hydrolase and transformant
JPH09104698A (en) Kaurene synthetase
KR100569165B1 (en) Peroxiredoxin 1 of Chicken and Nucleic Acid Molecules Encoding the Same
Houtz et al. Inhibitors of plant peptide deformylase for use as broad-spectrum herbicides and methods for identifying the same
JP2008253248A (en) Oxidation-resistant ascorbate peroxidase
Kim Biochemical and molecular studies on Phenylalanine ammonia lyase in the phytopathogenic fungus Ustilago maydis
Thelen Purification, characterization and molecular analysis of the mitochondrial pyruvate dehydrogenase complex from maize
MXPA00006220A (en) Plant galactose dehydrogenase
EP2611283A2 (en) Oil globule protein and uses thereof

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION